Preparing for Fall Respiratory Illness Season: A Guide for St. Petersburg Physicians

Oct 9

As fall approaches, physicians in St. Petersburg, Florida, should prepare for the seasonal increase in respiratory illnesses, including influenza, respiratory syncytial virus (RSV), and COVID-19. Although Florida's subtropical climate differs from that of colder regions, respiratory viruses remain an important cause of outpatient visits, emergency department utilization, and hospital admissions during the fall and winter months. Older adults, young children, pregnant patients, immunocompromised individuals, and patients with chronic cardiopulmonary conditions are particularly vulnerable to severe disease.

For physicians practicing in the greater St. Petersburg and Pinellas County area, effective seasonal preparation requires more than vaccine administration. It involves strengthening clinical workflows, maintaining diagnostic readiness, recognizing patients who may benefit from early antiviral treatment, implementing appropriate infection prevention measures, and communicating evidence-based recommendations clearly.

With influenza activity already emerging earlier than usual in some parts of the United States during autumn 2026, practices should avoid relying solely on traditional seasonal timelines. Local surveillance, timely clinical assessment, and proactive prevention should guide decision-making throughout the season.

1. Understand the Seasonal Respiratory Disease Landscape

Influenza, RSV, and SARS-CoV-2 continue to contribute substantially to acute respiratory disease, but their epidemiology, clinical presentations, and treatment considerations differ.

Influenza: Often presents with an abrupt onset of fever, myalgia, headache, fatigue, and cough. Complications include viral or secondary bacterial pneumonia, exacerbations of chronic disease, and cardiovascular events.
Respiratory syncytial virus (RSV): Can cause bronchiolitis and pneumonia in infants and young children, as well as severe lower respiratory tract disease in older adults and individuals with underlying medical conditions.
COVID-19: Continues to cause acute respiratory illness and may precipitate hospitalization, cardiovascular complications, or persistent post-acute symptoms, particularly in higher-risk populations.

Clinical presentation alone may not reliably distinguish these infections. Coinfections are also possible, and other respiratory pathogens remain relevant to the differential diagnosis.

Physicians should monitor the Florida Department of Health, Pinellas County public health communications, and the Centers for Disease Control and Prevention (CDC) for updated information on viral activity, circulating strains, and emerging trends. National surveillance provides useful context, but regional data and local healthcare utilization patterns are more actionable when determining testing strategies, staffing requirements, and infection prevention measures.

2. Review Vaccination Recommendations and Close Immunization Gaps

Vaccination remains a central component of respiratory disease prevention. Before the season reaches peak activity, practices should review immunization records, identify eligible patients, confirm product availability, and establish systems for documenting and communicating vaccination status.

Influenza vaccination

The CDC recommends annual influenza vaccination for individuals aged six months and older who do not have a contraindication. The 2026–2027 influenza vaccines have updated viral components, reflecting recommendations intended to improve protection against strains anticipated to circulate during the season.

Physicians should prioritize timely vaccination for older adults, pregnant patients, young children, individuals with chronic medical conditions, and others at increased risk of complications. For adults aged 65 years and older, the CDC preferentially recommends high-dose inactivated, adjuvanted inactivated, or recombinant influenza vaccines when available and appropriate.

Vaccination by the end of October is a useful target, although immunization should continue while influenza viruses are circulating and vaccine remains available. Avoid missed opportunities by offering vaccination during routine visits, chronic disease follow-ups, and other appropriate encounters.

COVID-19 vaccination

For the 2026–2027 season, the CDC's published guidance recommends the updated COVID-19 vaccine for adults aged 18 years and older. Recommendations for children depend on age and immune status, with shared clinical decision-making recommended for children aged 6 months through 17 years who are not moderately or severely immunocompromised.

Because COVID-19 vaccine guidance, product labeling, and dose schedules may evolve, physicians should consult the current CDC clinical guidance and applicable FDA labeling before administration. Review each patient's age, vaccination history, immune status, and risk of severe disease when determining the appropriate product and schedule.

RSV immunization

RSV prevention is especially important for older adults, infants, and young children. Current CDC guidance recommends a single dose of an RSV vaccine for all adults aged 75 years and older and adults aged 50–74 years at increased risk of severe RSV disease. RSV vaccination is not currently an annual recommendation for adults who have already received a dose.

For infant protection, clinicians should assess maternal RSV vaccination during the recommended gestational window and determine whether an infant RSV monoclonal antibody is indicated. Depending on eligibility and prior protection, nirsevimab or clesrovimab may be appropriate for infants, while nirsevimab is also recommended for certain young children entering a second RSV season.

In obstetric, pediatric, primary care, and geriatric settings, coordination between clinicians can reduce gaps in preventive coverage.

Clinical reference: CDC guidance for influenza vaccination, COVID-19 vaccination, and RSV immunization.

3. Strengthen Diagnostic Readiness and Clinical Decision-Making

Timely identification of respiratory pathogens can inform treatment, infection prevention, and patient disposition. Before seasonal activity increases, practices should review testing protocols, ensure access to appropriate diagnostic assays, and clarify when molecular testing or multiplex respiratory panels are warranted.

Testing decisions should reflect the patient's clinical presentation, risk factors, symptom duration, and whether results will influence management.

Consider testing particularly when:

A patient has a high risk of severe disease and a pathogen-specific treatment may be indicated.
The diagnosis would influence antiviral prescribing or the need for additional clinical evaluation.
A patient presents with severe, progressive, or atypical symptoms.
Results may guide infection prevention, cohorting, or outbreak management in a healthcare or congregate setting.
The differential diagnosis remains broad or identification of coinfection would alter treatment.

Rapid antigen tests may be useful in selected settings, but their sensitivity varies by pathogen, assay, and timing. A negative result should not automatically exclude infection when clinical suspicion remains high. Molecular assays generally offer greater sensitivity, although testing should still be guided by clinical utility.

Physicians should also recognize that a positive viral test does not exclude bacterial coinfection. Findings such as focal pulmonary abnormalities, hemodynamic instability, recurrent fever after initial improvement, or a deteriorating clinical course may warrant further investigation.

4. Identify Candidates for Early Antiviral Treatment

Early treatment can reduce complications in appropriately selected patients, particularly those at increased risk of severe disease. Delays in diagnosis or treatment may result in missed opportunities to improve outcomes.

For suspected or confirmed influenza, antiviral treatment should be initiated promptly in hospitalized patients, those with severe or progressive illness, and patients at increased risk of complications. Treatment is most beneficial when started early, ideally within 48 hours of symptom onset; however, eligible high-risk or severely ill patients may still benefit when treatment begins later. Treatment decisions should not be delayed while awaiting test results when clinical suspicion and patient risk justify empiric therapy.

Oseltamivir is an important treatment option, with dosing adjusted for renal function when indicated. Other influenza antivirals may be appropriate depending on age, clinical setting, contraindications, and current guidance.

For COVID-19, clinicians should identify eligible high-risk outpatients early enough to initiate treatment within the authorized or recommended treatment window. Medication selection requires review of renal and hepatic function, potential drug interactions, contraindications, and current prescribing guidance.

There is no routinely recommended specific antiviral treatment for uncomplicated RSV infection in most immunocompetent patients. Management is generally supportive, with attention to oxygenation, hydration, respiratory effort, and complications. Selected severely immunocompromised patients may require specialist consultation.

A standardized intake workflow that records symptom onset, oxygen saturation when indicated, comorbidities, renal function, current medications, and immune status can help clinicians make timely treatment decisions.

5. Reinforce Infection Prevention and Healthcare Workforce Preparedness

Respiratory virus season can increase transmission in waiting rooms, examination areas, hospitals, and long-term care facilities. Infection prevention protocols should be reviewed before patient volumes rise.

Recommended operational measures include:

Screening patients for respiratory symptoms during scheduling and check-in.
Providing masks and encouraging their use by symptomatic patients, particularly in crowded clinical settings or when transmission is elevated.
Improving ventilation and maintaining appropriate air filtration where feasible.
Reinforcing hand hygiene, respiratory etiquette, and environmental cleaning.
Applying pathogen-specific precautions and personal protective equipment according to current infection prevention guidance.
Ensuring that staff understand procedures for reporting illness, staying home when appropriate, and returning to work safely.
Reviewing plans for managing suspected respiratory outbreaks in healthcare and congregate-care settings.

Practices should maintain adequate supplies of personal protective equipment, diagnostic materials, and commonly used medications. Staffing contingency plans are also important, particularly for smaller offices where a limited number of absences can disrupt clinical operations.

6. Anticipate the Needs of High-Risk Patient Populations

Not all patients face the same likelihood of complications. A risk-stratified approach helps direct prevention and follow-up resources to those most likely to benefit.

Older adults and patients with chronic disease: Assess vaccination status, cardiopulmonary reserve, functional status, and medication-related risks. Influenza, COVID-19, and RSV can precipitate exacerbations of chronic obstructive pulmonary disease, asthma, heart failure, and other chronic conditions.

Pregnant patients: Review influenza and COVID-19 vaccination status, discuss maternal RSV vaccination eligibility and timing, and provide clear guidance on when respiratory symptoms warrant prompt evaluation.

Infants and young children: Evaluate feeding, hydration, work of breathing, apnea risk, and signs of respiratory distress. Confirm eligibility for maternal RSV vaccination or infant monoclonal antibody protection and educate caregivers about warning signs.

Immunocompromised patients: Individualize preventive strategies, review current vaccine guidance, and maintain a low threshold for appropriate diagnostic evaluation and specialist involvement.

Patients in long-term care or other congregate settings: Coordinate vaccination, symptom surveillance, testing, and infection control with facility leadership. Early recognition and prompt public health consultation may be important when a cluster of cases emerges.

Equitable access should remain a priority. Transportation barriers, limited appointment availability, language differences, and vaccine hesitancy can interfere with preventive care. Practices can mitigate these barriers through reminder systems, convenient vaccination opportunities, interpreters, and clear patient education.

7. Prepare Practice Operations for Increased Demand

Clinical readiness depends on reliable operational systems as well as medical knowledge. A pre-season review should address the following areas:

Inventory management: Confirm vaccine availability, appropriate storage conditions, expiration dates, and access to diagnostic supplies and treatment medications.
Electronic health record workflows: Build prompts for vaccination status, risk assessment, symptom onset, testing, and follow-up.
Appointment triage: Establish protocols for determining which patients can be managed remotely, which require in-person assessment, and which need urgent or emergency evaluation.
Patient communication: Prepare evidence-based messages about vaccination, respiratory hygiene, testing, antiviral treatment, and when to seek care.
Referral and escalation pathways: Confirm access to emergency services, specialty consultation, and hospital evaluation when necessary.
Performance monitoring: Track vaccination coverage, testing turnaround times, antiviral prescribing delays, emergency referrals, and missed follow-up appointments.

Telehealth can be useful for selected patients with mild symptoms and low immediate risk, provided clinicians can adequately assess the presentation and arrange in-person evaluation when necessary. Remote care should not substitute for urgent examination when respiratory distress, hypoxemia, altered mental status, dehydration, or other serious findings are suspected.

8. Communicate Clearly About Prevention and When to Seek Care

Physician recommendations strongly influence patient decisions about vaccination and other preventive measures. Discussions should be direct, individualized, and grounded in the patient's medical history and preferences.

Rather than relying exclusively on general messaging, clinicians should explain how a specific respiratory infection may affect an individual with diabetes, cardiovascular disease, chronic lung disease, pregnancy, or immunocompromise. Address concerns about adverse effects, expected vaccine benefits, and the limitations of vaccination without overstating protection.

Patients should also receive practical guidance on symptom monitoring and infection prevention. Advise prompt clinical contact when respiratory symptoms develop in a high-risk individual, since treatment eligibility may depend on how quickly care begins.

Emergency evaluation is warranted for signs such as significant difficulty breathing, persistent chest pain or pressure, new confusion, cyanosis, severe dehydration, or other evidence of clinical deterioration. Infants with apnea, marked respiratory effort, poor feeding, or reduced responsiveness require urgent assessment.

Conclusion

Preparing for fall respiratory illness season in St. Petersburg requires coordinated preventive care, timely diagnosis, appropriate treatment, and dependable clinical operations. Although the timing and intensity of influenza, RSV, and COVID-19 activity vary from year to year, physicians can reduce avoidable morbidity by identifying high-risk patients early, closing immunization gaps, maintaining diagnostic readiness, and initiating indicated treatment without unnecessary delay.

For the 2026–2027 season, practices should combine current national clinical guidance with local surveillance and the needs of their patient populations. A proactive, evidence-based approach will help St. Petersburg physicians protect vulnerable patients, maintain continuity of care, and strengthen healthcare system readiness throughout the respiratory virus season.

Clinical guidance note: Recommendations and vaccine eligibility may change as new evidence, regulatory decisions, and public health guidance emerge. Clinicians should verify current CDC, FDA, and Florida Department of Health guidance at the point of care.